Let's see what the numbers say about Abbott (ABT).
The Affordable Care Act is creating a variety of challenges and opportunities for health care companies. Medtronic is embracing a provision designed to reduce re-admissions by expanding into the home monitoring market.
Keep an eye on Amarin, Cubist, and Abaxis -- they could make big moves during today's trading.
While this product is unquestionably remarkable, are you considering the risks before buying Pharmacyclics at inflated prices?
With a share price gain of more than 1,000% over the trailing 12 months, this company and its CEO are at the forefront of cracking a tough-to-treat disease.
Even biotechnology stocks could use a facelift now and then. Alkermes CEO Richard Pops outlines the new path his company will be taking moving forward.
Buyout fever could be taking hold in the world of biotech. These 3 stocks show fever symptoms already.
It was all fun and games for the biotech sector this week with a new drug filing, positive clinical data, and buyout rumors fueling the following stocks higher.
Mixed clinical data, a potential buyout, an untimely clinical hold, and a potential breakthrough therapy highlight this week's top biotech stories.
Written off for dead in 2009, this drug may show increased efficacy at higher doses.